Recently, several molecular-targeted drugs, targeting proteins such as the fusion protein of echinoderm microtubule-associated protein-like 4 (EML4) with anaplastic lymphoma kinase (ALK) (EML4-ALK) and epidermal growth factor receptor tyrosine kinase (EGFR TK), have been launched as therapeutic drugs for lung cancer. Here, ALK is linked to lung carcinoma.